
GoodRx Holdings Inc (NASDAQ:GDRX) shares are pulling back Tuesday morning, as investors potentially take profits following Monday’s surge. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk to expand access to popular GLP-1 medications.
What To Know: Under the new program, GoodRx will offer all strengths of Ozempic and Wegovy to eligible self-paying patients for a fixed monthly price of $499. The company says the discount is available immediately through GoodRx’s platform at over 70,000 retail pharmacies across the nation.